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Hypoxic EMT-6 tumour cells displayed a high level of inducible nitric oxide synthase (iNOS) and an increased radiosensitivity after a
16h exposure to lipopolysaccharide, a known activator of nuclear factor-kB (NF-kB). Both iNOS activation and radioresponse were
impaired by the NF-kB inhibitors phenylarsine oxide and lactacystin. Contrasting to other studies, our data show that inhibition of NF-
kB may impair the radioresponse of tumour cells through downregulation of iNOS.
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Nuclear factor-kB (NF-kB) is part of the early response of
mammalian cells to ionizing radiation and triggers cellular defence
mechanisms. In line, an aberrant regulation of the NF-kB pathway
was found to contribute to the intrinsic hypersensitivity of ataxia
telangiectasia fibroblasts to radiation (Jung et al, 1995). Other
studies have shown that disruption of NF-kB signalling by
transfection with the super-repressor IkBa (Wang et al, 1996;
Miyakoshi and Yagi, 2000), by indomethacin (Bradbury et al, 2001)
or by the proteasome inhibitors MG-132 and PS-341 (Pajonk et al,
2000; Russo et al, 2001) enhances the radiosensitivity of tumour
cells. Based on these findings, NF-kB is currently considered to be
a promising molecular target for tumour radiosensitisation.
However, all these studies were performed in aerobic cells and it
remains unclear whether such a strategy is applicable in the
hypoxic tumour microenvironment, which modifies both radio-
sensitivity and transcriptional responses. One of these hypoxia-
responsive genes appears to be inducible nitric oxide synthase
(iNOS), which is frequently overexpressed in solid tumours
(Thomsen et al, 1995). This enzyme utilises L-arginine to produce
nitric oxide (NO), which seems to be carcinogenic and proangio-
genic (Ambs et al, 1998).
The mechanism by which iNOS is induced in tumour cells is not
clarified yet, but the iNOS promoter is known to contain specific
binding sites for hypoxia-inducible factor 1 (HIF-1) and for NF-kB
(Xie et al, 1993; Melillo et al, 1995). Our recent study (Van den
Berge et al, 2001) and other reports (Melillo et al, 1996) indicate
that hypoxia itself does not activate iNOS, but rather sustains the
induction of iNOS by proinflammatory stimuli. Many of them, like
lipopolysaccharide (LPS), interleukin-1b (IL-1b) and tumour
necrosis factor a (TNF a), activate iNOS, through the NF-kB
signalling pathway and this mechanism may underlie the
constitutive NF-kB activity observed during chronic inflammation
and tumorigenesis (Karin et al, 2002). Besides this, the tumour
microenvironment, which is characterised by transient hypoxia/
reoxygenation as a result of poorly organized vasculature and
sporadic occlusions of blood vessels, may directly activate NF-kB
since this factor is sensitive to oxidative stress (Koong et al, 1994).
Interestingly, the causative role of iNOS-mediated NO synthesis in
hypoxia/reoxygenation injury is well established (Toomey et al,
2001) and NO appeared to affect the function of different proteins
including NF-kB and HIF-1 by their nitrosylation (Palmer et al,
2000; Marshall and Stamler, 2001).
Our laboratory has recently shown that activation of iNOS by
proinflammatory cytokines in EMT-6 mammary carcinoma cells
results in high output of NO, sufficient to reverse hypoxia-induced
radioresistance by analogy to chemical NO donors (Mitchell et al,
1993; Verovski et al, 1996; Janssens et al, 1998, 1999). Moreover,
the potency of cytokines to activate iNOS was drastically increased
under hypoxic conditions (Van den Berge et al, 2001). We
therefore speculated that inhibition of NF-kB might impair rather
than enhance the radiosensitivity of hypoxic tumour cells through
transcriptional downregulation of iNOS.
To verify this hypothesis, we exposed EMT-6 tumour cells to
LPS in 1% oxygen, modelling the hypoxic tumour microenviron-
ment, and examined the activation of NF-kB, the induction of
iNOS and the hypoxic cell radiosensitivity. Next, we evaluated the
effects of lactacystin and phenylarsine oxide (PAO), which inhibit
NF-kB at the level of the proteasome and DNA-binding,
respectively.
MATERIALS AND METHODS
Chemicals
Lactacystin was purchased from Alexis Corporation (Laufelfingen,
Switzerland). Other chemicals were obtained from Sigma Chemical
Co. (St Louis, MO, USA), unless otherwise stated.
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Murine mammary adenocarcinoma EMT-6 cells were kindly
provided by Dr Edith Lord (University of Rochester, Cancer
Center, New York, USA). Cells (passage 15–40) were cultured in
RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10%
bovine calf serum (HyClone Laboratories Inc. Logan, UT, USA) in
plastic flasks (Greiner, Frickenhausen, Germany).
Hypoxic treatment
EMT-6 monolayer cultures grown to early confluence were
exposed to lactacystin for 3h or to PAO for 10min and washed.
Afterwards, LPS was added to activate NF-kB and iNOS under
hypoxic conditions. To obtain hypoxia, culture flasks were placed
in sealed chambers and subjected to repeated vacuum evacuation
and injection of nitrogen/CO2-balanced gas containing 1% oxygen.
Further processing of cells was done as described below.
iNOS expression by Western blotting
After a 16h incubation in hypoxia, cell lysates (from 1 10
5 cells)
were resolved in a 7.5% polyacrylamide–SDS gel and transferred
onto HyBond super nitrocellulose membrane (Amersham, Buck-
inghamshire, UK). The membranes were stained with Ponceau to
confirm the equal loading of proteins in the different lanes. After
destaining, the blots were incubated for 1h at 201C with the
primary monoclonal antibody to iNOS (Affiniti Research Products,
Exeter, UK) and analysed by an immunoperoxidase-based ECL
technique (Pierce, Rockford, IL, USA), according to the manufac-
turer’s protocol.
Determination of nitrite
After iNOS induction, cultures were reincubated during 6h in
normoxia to accumulate nitrite, an oxidative product of NO. The
nitrite level in the medium was determined using the Griess
reaction as described previously (Van den Berge et al, 2001). These
values were normalised to 200000 cells per well, in a 24-well plate.
NF-jB activity by EMSA
After a 1h incubation in hypoxia, the binding activity of NF-kB
was analysed in nuclear extracts essentially as described elsewhere
(Plaisance et al, 1997). Based on literature data on the mouse iNOS
promoter (Xie et al, 1993), the 34bp NF-kB consensus primers
encoding the sequence 50-AGG ATG TGC TAG GGG GAT TTT CCC
TCT CTC TCTG -30 (NF-kB motif in bold) were synthesised by
Invitrogen (Merelbeke, Belgium), annealed and labelled with 32P
by the Klenow reaction. In competition assays, a 50-fold excess of
unlabelled NF-kB consensus or its mutant (Santa Cruz Biotechnol-
ogy, CA, USA) was included in binding reactions. In supershift
assays, monoclonal antibodies against the p65 (C-20) and p50 (D-
17) subunits of NF-kB (Santa Cruz Biotechnology, CA, USA) were
used.
NF-jB expression by Western blotting
Nuclear extracts were resolved in a 10% polyacrylamide–SDS gel
and stained with the anti-p65 monoclonal antibody (Santa Cruz
Biotechnology, CA, USA). Further blotting and ECL analysis were
performed as described above for iNOS.
Radiosensitivity
After 16h incubation in hypoxia, cells were collected by
trypsinisation and the hypoxic cell radioresponse was estimated
as described earlier (Van den Berge et al, 2001). Briefly,
0.5 10
6cells in 100ml of medium were placed in conical plastic
tubes and pellets were produced by centrifugation at 300g for
5min. Metabolic oxygen depletion in pellets was induced by a
3min incubation at 371C prior to radiation. Cell pellets were
irradiated at 371C at doses 0–20Gy and cell survival was measured
by an 8-day colony formation assay.
Statistics
All assays were repeated at least three times. Data are expressed as
means (symbols) with corresponding standard deviations (bars).
The radioresponse of the different experimental groups were
compared by one-way ANOVA.
RESULTS
EMT-6 cultures were exposed to 0.1mgml
 1 LPS in 1% oxygen to
model the reduced oxygenation in solid tumours. Afterwards, the
binding activity of NF-kB in nuclear extracts was examined by
EMSA. The activation of NF-kB was maximal after a 60min
exposure (Figure 1A), which was chosen for further experiments.
The binding of NF-kB to the probe was blocked by competition
with unlabelled NF-kB sequence, but not with its mutant
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Figure 1 Effect of lactacystin and PAO on nuclear NF-kB expression and
binding activity in hypoxic EMT-6 cells. (A) Cultures were exposed to
0.1mgml
 1 LPS in 1% oxygen for 0–90min and afterwards analysed for
the binding activity of NF-kB in nuclear extracts by EMSA. (B) An analysis
of the NF-kB composition was performed using anti-p65 and anti-p50
antibodies. The specificity of NF-kB binding was confirmed by inclusion of
unlabelled (cold) NF-kB consensus and its mutant in the binding reactions.
(C, D) The effect of a 3h pretreatment with lactacystin (LC) and a 10min
pretreatment with PAO on the expression and binding activity of NF-kB
was evaluated after a 60min exposure to 0.1mgml
 1 LPS. The figure is
representative of three independent experiments.
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British Journal of Cancer (2003) 88(1), 120–124 & 2003 Cancer Research UK(Figure 1B). The addition of either anti-p65 antibody or anti-p50
antibody induced a supershift, indicating the appearance of the
p50/p65 heterodimer in the nuclei. To inhibit NF-kB, cells were
pretreated with the proteasome inhibitor lactacystin, which blocks
the activation step of NF-kB in the cytoplasm (Musial and Eissa,
2001), or with PAO, which inhibits NF-kB by modifying its vicinal
dithiol moiety (Oda et al, 2000). Both agents substantially
decreased the LPS-induced NF-kB activation as demonstrated in
Figure 1C and D. A maximal effect of lactacystin was observed after
a 3h pretreatment at 20–80mM, while PAO became already active
after a 10min pretreatment at 2–8mM. In line, Western blots
showed a decreased level of nuclear p65, suggesting that the
translocation of NF-kB to the nuclei rather than its specific activity
was affected.
To examine whether the NF-kB pathway controls the expression
of iNOS, EMT-6 cultures were exposed to 0.001–0.1mgml
 1 LPS
for 16h in 1% oxygen and analysed by Western blotting. LPS
induced a dose-dependent activation of iNOS (Figure 2A), which
resulted in accumulation of nitrite, an oxidative product of NO, as
determined by the Griess assay (Figure 3A). The production of
nitrite was completely abolished by aminoguanidine, a specific
metabolic inhibitor of iNOS. The induction of iNOS by 0.1mgml
 1
LPS was significantly higher in hypoxia compared to normoxia.
Both lactacystin and PAO inhibited the expression of iNOS and the
production of nitrite at essentially the same concentrations that
were efficient to inhibit the activation of NF-kB (Figure 2B, C and
3B). However, both agents–especially at low concentrations–were
less potent than aminoguanidine to inhibit the production of
nitrite.
In a final set of experiments, we evaluated the effect of
lactacystin and PAO on the hypoxic cellular radioresponse. First,
the radiosensitivity of hypoxic EMT-6 tumour cells after a 16h
exposure to 0.001–0.1mgml
 1 LPS in 1% oxygen was examined.
We observed a significant increase in hypoxic cell radio-
response at all three concentrations with a maximal effect at
0.01–0.1mgml
 1 (Po0.001; Figure 4A). Strikingly, a normoxic
incubation with LPS had little, if any, effect on radiosensitivity.
To examine whether the radiosensitivity of iNOS-expressing
tumour cells may be altered by NF-kB inhibitors, EMT-6
cells were pretreated for 3h with 40mM lactacystin or for 10min
with 4mM PAO and afterwards exposed to 0.1mgml
 1 LPS in
hypoxia. Both agents considerably decreased the hypoxic cell
radiosensitivity (Po0.001; Figure 4B), yet lactacystin was less
effective than PAO, in line with Griess data. The iNOS inhibitor
aminoguanidine decreased the hypoxic cell radiosensitivity to a
level comparable to that of PAO.
DISCUSSION
Aberrant NF-kB signalling has been associated with several aspects
of tumorigenesis, including stimulation of cancer cell proliferation,
angiogenesis, formation of metastasis and prevention of apoptosis
(Karin et al, 2002). Consistently, many tumour cells display
constitutively activated NF-kB, which might provide an advantage
to survive and to grow in a hypoxic microenvironment. Interest-
ingly, activation of NF-kB is promoted by hypoxia/reoxygenation
insults in the vasculature of tumours (Royds et al, 1998). Another
source of oxidative stress directed to NF-kB are reactive oxygen
intermediates produced in a cell type-specific manner by
lipoxygenase- and NADPH oxidase-dependent pathways (Bonizzi
et al, 1999).
NF-kB plays a crucial role not only in tumour development, but
also in the response of tumour cells to radiation. Consistently, NF-
kB inhibition has repeatedly been used as an approach to
radiosensitise tumour cells by stimulating apoptosis or by
inhibiting DNA repair (Wang et al, 1996; Miyakoshi and Yagi,
2000; Russo et al, 2001). We have delineated another downstream
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Figure 2 Effect of lactacystin and PAO on iNOS expression in hypoxic
EMT-6 cells. (A) EMT-6 cultures were exposed to 0.001–0.1mgml
 1 LPS
in 1% oxygen and afterwards analysed for the expression of iNOS by
Western blotting. The last lane illustrates the iNOS induction by LPS in 21%
oxygen. (B, C) iNOS expression after a 3h pretreatment with lactacystin
(LC) and a 10min pretreatment with PAO followed by a 16h exposure to
0.1mgml
 1 LPS in 1% oxygen. The figure is representative of four
independent experiments.
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Figure 3 Effect of lactacystin and PAO on nitrite production by EMT-6
cells. (A) EMT-6 cultures were exposed to 0.0001–0.1mgml
 1 LPS for
16h in 1% oxygen and afterwards analysed for the accumulation of nitrite,
with or without 3mM aminoguanidine. (B) Nitrite production after a 3h
pretreatment with lactacystin (LC) and a 10min pretreatment with PAO
followed by exposure to 0.1mgml
 1 LPS in 1% oxygen.
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British Journal of Cancer (2003) 88(1), 120–124 & 2003 Cancer Research UKtarget of NF-kB, the cytokine/LPS-inducible form of nitric oxide
synthase (iNOS), which may respond to NF-kB inhibitors as well
and thereby modulate the radioresponse of tumour cells.
Conceivably, this model is relevant for tumours that display
constitutive NF-kB signalling to iNOS.
Indeed, the iNOS promoter of mammalian cells encodes specific
NF-kB binding sites, which are crucial in the activation of iNOS by
inflammatory stimuli (Xie et al, 1993). Second, in our model of
hypoxic EMT-6 cells, LPS treatment clearly induced translocation
of NF-kB to the nucleus and increased its binding activity to the
NF-kB consensus of the iNOS promoter, as revealed by Western
blotting and EMSA. Third, both the expression and activity of NF-
kB and iNOS were inhibited by PAO and lactacystin. This resulted
in inhibition of NO production, as determined by accumulation of
nitrite, an oxidative product of NO. Finally, PAO and lactacystin
significantly decreased the hypoxic radiosensitivity of EMT-6
tumour cells. A similar radioprotection was observed after
metabolic inhibition of iNOS by aminoguanidine. These effects
may be explained by downregulation of iNOS-mediated synthesis
of NO, a potent radiosensitiser that is produced from L-arginine
directly in the tumour cells (Janssens et al, 1998).
Contrasting to other studies performed in aerobic conditions,
our data clearly indicate that NF-kB inhibitors may impair the
radiosensitivity of tumour cells and that this effect is unmasked in
hypoxia. Therefore, hypoxia-responsive transcription factor(s) are
likely to sustain the induction of iNOS by LPS (shown here) or by
IL-1b and interferon-g (Van den Berge et al, 2001). Such a
mechanism was first shown in hypoxic macrophages (Melillo et al,
1995) and is probably operational in the hypoxic regions of solid
tumours wherein iNOS and HIF-1 were found to be active
(Thomsen et al, 1995; Dachs and Stratford, 1996; Ambs et al,
1998). Hence, HIF-1 signalling to iNOS might be another potential
target for NF-kB inhibitors, assuming they would be capable of
inactivating HIF-1. However, lactacystin is known to increase the
level of HIF-1 by blocking its degradation at the level of the
proteasome (Salceda and Caro, 1997) and PAO is known to induce
HIF-1 by a yet unknown mechanism (Sandau et al, 2001).
Therefore, the NF-kB pathway is the most likely target to explain
the downregulation of iNOS by both inhibitors in EMT-6 tumour
cells. In line, lactacystin was shown to inhibit NF-kB by blocking
the degradation of its inhibitory unit IkB, thereby inhibiting the
induction of iNOS in epithelial HEK293 cells (Musial and Eissa,
2001).
Recently, proteasome inhibitors have emerged as a novel class of
radiosensitisers and PS-341, a 26S proteasome inhibitor analogous
to lactacystin, has entered multiple phase 2 clinical trials (Elliott
and Ross, 2001). This strategy was established in vitro using
aerobic cultures and therefore addressed the intrinsic radio-
sensitivity of tumour cells. Till now, no data were available on the
radiomodulating effects of NF-kB and proteasome inhibitors in
conditions mimicking the hypoxic tumour microenvironment. Our
study for the first time demonstrates that NF-kB and proteasome
inhibitors may impair the hypoxic radioresponse of iNOS-
expressing tumour cells.
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